Biomarker: D002-IgE D farinae (Dust Mite)

Overview

D002-IgE measures immunoglobulin E (IgE) antibodies directed against the house dust mite Dermatophagoides farinae (Der f). IgE is an antibody involved in immediate allergic responses, including activation of mast cells and release of inflammatory mediators. A detectable or elevated result indicates sensitization to Der f, but does not by itself confirm clinical allergy or predict reaction severity. The test is clinically useful when interpreted with symptoms, exposure history, and other allergy-test findings to evaluate allergic rhinitis, asthma, or related respiratory disease.

Clinical Use Cases

Evaluate suspected house dust mite sensitization in people with allergic rhinitis, conjunctivitis, asthma, or other respiratory allergy symptoms.
Identify Der f as a potential environmental trigger when symptoms occur in homes or other indoor environments.
Support differential diagnosis when the clinical history suggests an inhalant allergy.
Provide an alternative to skin-prick testing when skin testing is unsuitable, including when extensive dermatitis or interfering medications are present.
Help guide environmental exposure-reduction counseling and consideration of allergen immunotherapy when clinically appropriate.
Support clinical or epidemiological research on dust-mite sensitization and respiratory allergy.

Specimen Types

Serum from venous blood.
Plasma may be accepted by some validated laboratory assays, according to the assay manufacturer’s requirements.
Skin test material is not a specimen for this biomarker, although skin-prick testing is a separate method for assessing dust-mite sensitization.

Measurement Methods

Quantitative or semiquantitative serum allergen-specific IgE immunoassay.
Fluorescence enzyme immunoassay, including widely used solid-phase platforms.
Enzyme-linked immunosorbent assay (ELISA).
Immunoblot or line immunoassay.
Multiplex allergen microarray or component-resolved immunoassay, when available.
Skin-prick testing with standardized Der f extract is a separate in-vivo method commonly used to assess sensitization.

Test Preparation and Influencing Factors

Fasting is generally not required for a specific-IgE blood test.
Routine allergy blood testing usually requires no special preparation, but medication instructions should be confirmed with the healthcare professional.
Antihistamines generally have less effect on blood specific-IgE measurements than on skin-prick testing; some clinical services may still provide medication-specific instructions.
Do not stop prescription or over-the-counter medicines unless instructed by a healthcare professional.
Results may vary with the assay platform, calibration, reporting units, reference ranges, and positivity thresholds.
A positive result indicates immunologic sensitization and must be correlated with compatible symptoms and exposure. It does not establish that Der f causes symptoms in every exposure setting.
The concentration of Der f-specific IgE does not reliably predict the severity of a future allergic reaction.
Total IgE, age, concurrent allergic sensitizations, cross-reactivity, and the timing of disease evaluation may influence interpretation.
Skin-prick testing, if performed instead of or alongside blood testing, can be affected by antihistamines, some other medications, skin disease, and the quality of the allergen extract.